Last reviewed · How we verify

NCT02346968

Evaluation of CAF22 After Renal Transplantation

Completed Last updated 28 August 2019
What this trial tests

trial testing Blood and urine sampling in Kidney Transplantation in 99 participants. Completed in 27 September 2018.

Timeline
8 October 2014
Primary endpoint
27 September 2018
27 September 2018

Quick facts

Lead sponsorInsel Gruppe AG, University Hospital Bern
StatusCompleted
Study typeOBSERVATIONAL
Enrollment99
Start date8 October 2014
Primary completion27 September 2018
Estimated completion27 September 2018
Sites2 locations across Switzerland, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Insel Gruppe AG, University Hospital Bern

Who can join

Adults 18 to 80, any sex, with Kidney Transplantation or Delayed Graft Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Established markers of kidney function, such as creatinine, have considerable limitations in the diagnosis of delayed graft function (DGF) after kidney transplantation (KT). Indeed, creatinine does not accurately reflect minor changes of renal function as its levels change only upon significant fluctuations of the latter. CAF22 is a molecule which arises from the degradation of a larger protein and it is proposed to be a reliable and more sensitive marker of renal function. This study aims to further clarify this issue by measuring blood and urine concentrations of CAF22 and comparing them with creatinine levels before and after KT. The main assumption is that blood CAF22 levels could serve as a more sensitive kidney function biomarker than creatinine post-KT to detect DGF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood and urine sampling

Trials testing the same drug.

Other recruiting trials for Kidney Transplantation

Currently open trials in the same condition.

Other Insel Gruppe AG, University Hospital Bern trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02346968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing